Ignite Creation Date:
2024-05-06 @ 1:37 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04077892
Status:
COMPLETED
Last Update Posted:
2019-09-04
First Post:
2019-09-01
Brief Title:
Compare the Effect of INS Alone and Added LTRA in Treatment of SAR
Sponsor:
Beijing Tongren Hospital
Organization:
Beijing Tongren Hospital
Study Overview
Official Title:
A Randomized Trial of Comparing a Combination of Montelukast and Budesonide With Budesonide in Allergic Rhinitis
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is not proven unequivocally whether a combination of an intranasal corticosteroids INS and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the treatment of severe allergic rhinitis AR We performed a randomized open-label study in 46 seasonal AR subjects receiving budesonide BD 256ug plus montelukast MNT 10 mg or BD alone 256ug for 2 weeks Visual analog scale VAS scores nasal cavity volume NCV nasal airway resistance NAR and fractional exhaled nitric oxide FeNO were assessed before and at end of treatments as the primary treatment outcomes Similarly histamine eosinophil cationic protein ECP and cysteinyl-leukotrienes Cyslts in nasal secretion and Th1Th2 cells in nasal mucosa were evaluated as the secondary treatment outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None